INTERNEURON DEXFENFLURAMINE COGNITIVE STUDY FINDS NO EVIDENCE OF NEUROTOXICITY; ADVISORY COMMITTEE RECOMMENDS OBESITY THERAPY BY SLIM MARGIN
A 72-patient study of Interneuron's Redux (dexfenfluramine) assessing cognitive function provides a "reassuring lack of evidence of neurotoxicity," FDA Medical Officer Leo Lutwak, MD/PhD, told the Endocrinologic & Metabolic Drugs Advisory Committee Nov. 16.
You may also be interested in...
Amylyx’ Second Chance Advisory Committee: Two Quasi-Precedents
US FDA’s plan to reconvene an advisory committee for a second look at Amylyx’ ALS drug AMX0035 is a remarkable twist in the ongoing review. It is essentially unprecedented, though there are two examples from the 1990s that offer some parallels.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials